Cytek Biosciences, Inc. announced that it expects to receive $15 million in funding
December 26, 2016
Share
Cytek Biosciences, Inc. announced that it will issue 15,000,000 series B preferred share at a price of $1 per share for the gross proceeds $15,000,000 on December 27, 2016. The preferred shares will be entitled to receive non-cumulative dividend at rate of 8% per annum and will be convertible into common shares at a fixed conversion price of $1 per share. The shares are convertible, participating and redeemable. The transaction will be raised at post money valuation of $39,500,000.
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.
CYTEK BIOSCIENCES, INC. 
